Background: B cells undergo maturation and class-switching in response to antigen exposure and T-cell help. Early B-cell differentiation has not been defined in patients with early-onset atopic dermatitis (AD). Objective: We sought to define the frequency of B-cell subsets associated with progressive B-cell maturation and IgE class-switching. Methods: We studied 27 children and 34 adults with moderateto-severe AD (mean SCORAD score, 55 and 65, respectively) and age-matched control subjects (15 children and 27 adults). IgD/CD27 and CD24/CD38 core gating systems and an 11-color flow cytometric panel were used to determine the frequencies of circulating B-cell subsets. Serum total and allergen-specific IgE (sIgE) levels were measured by using ImmunoCAP. Results: Compared with adults, children showed T-cell predominance in the skin. Circulating CD19 1 CD20 1 B-cell counts were lower in patients with pediatric AD than in control subjects (24% vs 33%, P 5 .04), whereas CD3 1 T-cell counts
Atopic dermatitis (AD) presents 2 main features, cutaneous inflammation and association with atopy, in which IgE plays a major role, particularly in patients with extrinsic disease.
1 Early (pediatric onset) AD is linked to subsequent development of allergic rhinitis and asthma, constituting the atopic march, 2 in which skin inflammation usually precedes the development of other atopic disorders. [3] [4] [5] The current view is that a disrupted skin barrier promotes allergic sensitization and T H 2 activation, which in turn predispose patients to systemic allergies. 2, 6 Atopy, which is defined as the tendency to have enhanced IgE levels and sensitization in response to environmental allergens, 7 links different components of the atopic march. Although epicutaneous sensitization can evoke systemic allergies, 2 it is unclear whether AD is immunologically a prerequisite to development of other atopic disorders. 6 Across the atopic spectrum, both T and B cells are believed to contribute to pathogenesis. Although in adults cutaneous lesions are largely T cell driven, B-cell/T-cell interactions are involved in atopy. [8] [9] [10] [11] [12] AD has its onset at a time window during which the adaptive immunity (memory T-and B-cell acquisition) is shaped through antigen exposure. Recent work has established associations of early AD with defined memory T-cell subsets. 13 B cells undergo a more complex differentiation that starts in the bone marrow (BM) and involves various mature subsets that express the IgE isotype and are defined by standard phenotypic markers. Transitional (CD38 11 CD24 11 ) B cells constitute the youngest circulating subset emigrating from BM, 14 
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). 18 In adults, reflecting decades of disease activity, we found a unique B-cell signature in skin and blood 19 that was correlated with memory T-cell activation, disease severity (SCORAD score), and IgE levels, which is in line with concurrence of other atopic manifestations. Delineating the sequence of B-cell differentiation in patients with early-onset AD relative to T-cell activation and clinical parameters is needed to elucidate early changes that predispose to the atopic march. However, such phenotyping has not been defined in children. Thus we studied B-cell subsets in blood of young children (<5 years old) with AD, within 6 months of disease onset. Results show that early-onset AD is characterized by aberrant B-cell maturation, T-cell predominance, and a complex network of associations between activated memory T cells, B cells, and serum-specific IgEs (sIgEs) to environmental and food allergens.
METHODS

Patients' characteristics and blood samples
Blood was obtained (after written, institutional review board-approved parental [<18 years old] and patient [> _12 years old] informed consent) from 27 children (12 female and 15 male children; mean, 1.52 years old) and 34 adults (15 female and 19 male adults; mean, 45.55 years old) with moderate-tosevere AD and 15 pediatric (8 female and 7 male subjects; mean, 2.21 years old) and 27 adult (10 female and 17 male subjects; mean, 40 years old) control subjects. No age (P 5 .08 and P 5 .17), sex (P 5 .74 and P 5 .2), or ethnicity (P 5 .13 and P 5 .9) disparities were observed between children and adults, respectively, within groups. Children were within 6 months of AD diagnosis. Serum IgE levels in adults with AD (normal, <200 kU/L) ranged from 4 to 44,210 kU/L (mean, 4,656 kU/L), and levels in children with AD (normal, <100 kU/L) ranged from 5.29 to 1,607 kU/L (mean, 261 kU/L). Control children's IgE levels ranged from 0 to 141 kU/L (mean, 26 kU/L). SCORAD scores were used to evaluate disease severity (adults: range, 38-93; median, 62; children: range, 20.8-83.6; median, 57.2). Despite some occurrences of positive sIgE levels in the control group, mean values were significantly lower than in the pediatric AD group (eg, mean egg sIgE in patients with AD vs control subjects: 4.26 vs 0.29 kU/L, P 5 .009; data not shown). Control subjects had no personal history of inflammatory skin disease and no personal/familial atopy. Demographic data are summarized in Table E1 in this article's Online Repository at www.jacionline.org.
Specific IgE measurements
Children with AD and their respective control subjects were screened for environment-specific sIgEs for the following allergens (codes appear in parentheses): Dermatophagoides pteronyssinus (d1), Dermatophagoides farinae (d2), egg white (f1), milk (f2), wheat (f4), peanut (f13), soybean (f14), hazelnut (f17), shrimp (f24), cockroach (Blatella germanica [i6]), staphylococcal enterotoxin A (m80), staphylococcal enterotoxin B (m81), and birch pollen (t3). Total and specific sIgE levels were determined by using Immuno-CAP (Thermo Scientific/Phadia, Uppsala, Sweden). The test result was considered positive if IgE levels exceeded 0.1 kU A /L. The measurement range for an undiluted sample was 2 to 5,000 kU/L. Because of the limited serum available, sIgE levels were measured for 14 children with AD and 12 control children. sIgE measurements were unavailable in adults (see Table E1 ).
of normal (n 5 7/n 5 14 [children/adults]), AD lesional (n 5 14/n 5 32), and AD nonlesional (n 5 12/n 5 16) skin sections from children and adults were stained with CD20 (B cells) and CD3 (T cells).
Statistical analysis
The Student t test was used to compare between variables. IgE values were log 10 -transformed before analyses. Unsupervised hierarchical clustering of variables or samples/patients was performed by using Spearman correlation as a similarity metric with average agglomeration algorithm and represented as a heat map with a dendrogram or as individual scatter plots. Scatterplots are accompanied by the regression line estimate for pediatric patients with AD and control subjects separately. A P value of less than .05 was considered significant. Heterogeneous (unpooled t test), homogeneous (pooled t test), and Mann-Whitney nonparametric P values appear in Table E2 in this article's Online Repository at www.jacionline.org.
RESULTS
We compared skin and blood from pediatric patients with early-onset moderate-to-severe AD less than 5 years old (n 5 27) with samples from age-matched control subjects (n 5 15) and adults with (n 5 34) and without (n 5 27) AD. Because the adult immune profile is already mature, we focused exclusively on pediatric groups to study associations between IgE-skewing, B-cell subsets, and memory T-cell acquisition.
CD3
1 T-cell counts are higher in pediatric skin, but CD20 1 B-cell counts are lower than in adults
To evaluate lymphocyte distribution in the skin, we performed IHC in control, nonlesional, and lesional AD skin. Less than 1% of infiltrating lymphocytes were B cells in early AD lesions, and significantly lower CD20
1 B-cell counts were seen in children versus adults for control, nonlesional, and lesional skin (control: 0.07 vs 2.1, P 5 .001; nonlesional: 0.3 vs 5.7, P 5 .05; lesional: 1.4 vs 19.8, P < .001; Fig 1, A and B) . Although B-cell counts were marginally increased in lesional versus control and lesional versus nonlesional skin (Fig 1, B) , they were not correlated with SCORAD scores in either pediatric or adult AD (P > .23; Fig 1,  C) , which is similar to our recent data.
19 Surprisingly, CD3
1 T-cell counts in pediatric control and pediatric nonlesional skin were higher than in adults (control: 130 vs 31, P < .001; nonlesional: 163 vs 70, P 5 .009; Fig 1, D and E) , and a large increase in T-cell numbers (comparable with adult AD) was measured in early AD lesions (Fig 1, D and E) . Contrary to B-cell counts, T-cell counts in lesional skin were significantly correlated with SCORAD scores in adults (r 5 0.44, P 5 .01) and showed a positive but nonsignificant correlation in children (Fig 1, F) .
Circulating B-cell frequencies are higher in children, whereas T-cell frequencies are increased in adults
Two flow cytometric approaches have been used to define B-cell subsets: CD27 versus IgD expression defines mature B-cell subsets and CD24 versus CD38 accounts for immature populations (Fig 2,  A and B) .
14,18 CD27 was used as a general memory marker, whereas IgD indicates naivety, 21, 22 with peripheral B cells classified as 2 ) subsets. 24 We have previously shown that circulating CD4
1 and CD8 1 memory T-cell counts are higher in adults versus children. 25 Conversely, CD19
1
CD20
1 peripheral B-cell counts were higher in children (control subjects: 33% vs 11%, P < .001; patients with AD: 24% vs 14%, P 5 .002; Fig 2, C) . Although pediatric control subjects had a higher circulating CD19
1
CD20
1 B-cell frequency than patients with AD (33% vs 24%, P 5 .04; Fig 2, C) , CD3
1 Tcell counts were higher in patients with AD (62% vs 52%, P 5 .05; Fig 2, D) . No B-cell or T-cell frequency differences were observed between adult control subjects and patients with AD (P > .36; Fig 2, C and D) . The B-cell/T-cell ratio decreases with age only in pediatric control subjects (r 5 20.48, P 5 .07; 
CD27
1 IgD 1 NSM and CD27 1 IgD 2 SM B-cell subset frequencies are greater in adults Overall, major B-cell frequencies were similar between pediatric patients with AD and control subjects (P > .57 for all subsets; Fig 3, A-D). Higher SM and NSM B-cell counts were seen in adults compared with children (SM B cells: patients with AD, 15% vs 2.3%; control subjects, 16% vs 1.9%; NSM B cells: patients with AD, 35% vs 7.5%; control subjects, 26% vs 8%; P < .001 for all; Fig 3, A and B) . As expected, naive B-cell counts were highest in children (patients with AD, 85% vs 47%; control subjects, 86% vs 51%; P < .001; Fig 3, C) . DN B cells comprised the only memory subset that was significantly higher in pediatric versus adult patients with AD (4.7% vs 4%, P 5 .01; Fig 3, D) . Primarily memory B-cell counts increased with age only in patients with AD (r 5 0.63, P 5 .0003; Fig 3, E) .
NSM, DN, and transitional IgE 1 cell counts were significantly higher in pediatric patients with AD versus control subjects (all P < .046; Fig 3, F-H) but correlated with SCORAD scores only for the transitional subset (r 5 0.4, P 5 .03; Fig 3, I ). No IgE 1 differences were observed between pediatric patients with AD and control subjects among other B-cell subsets (P > .1, data not shown).
Only adults have higher B-cell panactivation
CD25 expression and HLA-DR activation were both lower in children compared with levels in adults across all subsets (P <.06; see Fig E1 in this article's Online Repository at www.jacionline. org). Consistent with our recent report, 19 adults with AD had lower CD25
1 NSM B-cell counts compared with control subjects (26% vs 39%, P 5 .02; see Fig E1, F) , but no differences were observed in children, regardless of AD status (P 5 .46; see Fig E1, F) .
Prior publications showed that IgE sensitization to environmental and food allergens (sIgEs) is more frequent in pediatric patients with AD. 26 We measured levels of total and specific IgE to common allergens, 27, 28 and results were correlated with B-cell subsets, memory T-cell activation, age, and SCORAD scores. . Bar plots represent means 6 SEMs. *P < .05, **P < .01, and ***P < .001.
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IgE allergen sensitization increases with age and severity in pediatric patients with AD Similar to earlier reports, 29 significantly higher occurrence of IgE sensitization was found in pediatric patients with AD versus control subjects (P < .0001, see Table E1 ). We used Spearman correlation to define associations between IgE levels, age, and SCORAD scores (Fig 4 and see Table E3 in this article's Online Repository at www.jacionline.org). Highly significant positive correlations were found between age of children with AD (green rectangle) and multiple sIgEs, including birch pollen (r 5 0.6, P 5 .0008), Staphylococcus aureus enterotoxin A (SEA; r 5 0.6, P 5 .001), shrimp (r 5 0.4, D pteronyssinus (r 5 0.4, P 5.02), SEB (r 5 0.5, P 5.01), and shrimp (r 5 0.4, P 5 .04) sIgE levels were correlated with SCORAD scores (yellow rectangles). Multiple positive correlations were observed between SEA/SEB levels and age, SCORAD scores, and various food allergens (purple rectangles). Total IgE levels correlated with age (r 5 0.6, P 5 .0004) and with all measured sIgEs (black rectangles). No correlations were found in control subjects (data not shown). 
transitional, (3) mature naive, (4) plasmablast, and (5) new memory cell subsets. FSC, Forward scatter; SSC, side scatter. C and D, Circulating B-cell/T-cell frequencies. E-G, B-cell/T-cell ratio and age, NSM cell counts, and naive cell counts. Bar plots represent means 6 SEMs. *P < .05, **P < .01, and ***P < .001.
CD23
1 B-cell subsets are globally higher in patients with AD CD23, the low-affinity receptor for the Fc region of IgE (FcεRII), is involved in IgE expansion and B-cell activation. [30] [31] [32] We have shown that CD23 1 levels are higher in patients with AD versus patients with psoriasis or control adults and correlates with AD severity. 19 Here CD23 1 levels were significantly higher in pediatric patients with AD versus control subjects across all memory B-cell subsets (all P < .006; Fig 5, A-D) . Continued expression of CD23 1 B cells likely occurs in adults because higher frequencies were observed in blood of adults with AD (Fig 5) . Different CD23 1 cell subsets were positively correlated with sIgEs, such as CD23
1 NSM B-cell counts with shrimp sIgE levels (r 5 0.5, P 5 .007; see Fig E2 in this article's Online Repository at www.jacionline.org) and egg sIgE levels (r 5 0.5, P 5 .01; see Fig E2) . 1 NSM B-cell counts (P < .01; Fig 5, H-J) . Additionally, egg and shrimp sIgE levels were selectively correlated with skin-homing ICOS with B-cell memory subsets showed that CD38 2 CD24 1 primary memory B-cell counts correlated with T H 1 and T H 2 subsets selectively in pediatric patients with AD (T H 1 and T H 2 cells: r 5 0.6, P < .01; Fig 6, A and B) . Positive correlation was also found between total IgE levels and T H 2 cell counts (patients with AD: r 5 0.77, P 5 .001; Fig 6, C) . Additionally, as plotted in Fig E2, both T H 1 and T H 2 subsets in pediatric patients with AD correlated significantly with different sIgEs, including SEA (T H 1: r 5 0.5, P 5 .002; T H 2: r 5 0.6, P 5 .001), SEB (T H 1: r 5 0.6, P 5 .001; T H 2: r 5 0.4, P 5 .02), shrimp (T H 1 and T H 2: r 5 0.6, P < .01), birch pollen (T H 1: r 5 0.5, P 5 .008; T H 2: r 5 0.6, P 5 .001), and D pteronyssinus (T H 1: r 5 0.7, P < .0001; T H 2: r 5 0.5, P < .0001).
Allergen sensitization clusters with age and memory B-cell subsets in patients with AD
We also evaluated how different characteristics (age, SCORAD scores, and sIgE levels) related to different B-cell subsets and activated memory T cells. We performed unsupervised hierarchical clustering of all parameters using Spearman correlation for pediatric patients with AD and control subjects (see Figs E2 and E4 in this article's Online Repository at www.jacionline.org). In patients with AD, IgE sensitization to most allergens clustered with age, T H 1, T H 2, total IgE levels, SM, DN, and primarily memory B-cell subsets (green box), with SCORAD scores located nearby. In proximity to this cluster, wheat and peanut sIgEs FIG 4 . Spearman correlation plot demonstrating unsupervised hierarchical clustering of total and specific IgE levels, age, and SCORAD scores in pediatric patients with AD. Yellow, green, black, and purple rectangles mark positive correlations with SCORAD scores, age, total serum IgE levels, and SEA/SEB levels, respectively. The heat map shows the positive (red) or negative (blue) correlations of all parameters, with color intensity reflecting the strength of the correlation (21 to 11). Dendrograms are shown as a tree, representing the distance between variables. *P < .05, **P < .01, and ***P < .001.
clustered together with ICOS-activated Tem/Tcm cell and NSM B-cell counts (blue box). CD23 expression clustered together with CD3
1 T cells (purple box) and close to IgE 1 B-cell subsets (red box), reflecting the association between CD23 and IgE levels. Expectedly, these associations were not seen in control subjects (see Fig E4) .
DISCUSSION
Eighty-five percent of AD cases present before the age of 5 years, initiating the atopic march. However, comprehensive Bcell phenotyping at this key developmental stage and the relationship of B-cell phenotype to memory T-cell acquisition is unknown. This article outlines the B-cell profile of healthy subjects and pediatric patients with AD compared with adults and describes correlations between B-cell counts, T-cell counts, and IgE sensitization to food and environmental allergens (used as a measure of B-cell pathology) in patients with early AD.
The disproportionally higher CD3 1 T-cell than B-cell counts in skin lesions of pediatric patients with AD supports the role of primary T-cell activation in early disease. Congruent with previous reports, 33, 34 healthy children are characterized by increased circulating B-cell counts and decreased T-cell counts. Nevertheless, contrary to control subjects, children with AD exhibit dysregulated or accelerated lymphocyte development, with subsets prematurely converting toward the mature adult phenotype.
Naive cells constitute the main B-cell and T-cell lymphocyte populations during the early neonatal period. At this time point, memory T-cell and B-cell counts are at their nadir, and no AD skin manifestations are present. Preferential T H 2 and decreased T H 1 differentiation, as well as increased total and sIgE levels in cord blood presage atopy development. 20, 35, 36 Positive correlations between T H 2 cell counts and primarily memory B-cell counts in pediatric patients with AD highlight the association between these 2 subsets in patients with early disease.
Mouse studies showed that ICOS is vital for effective T-cell/ B-cell interactions, germinal center formation, CD40-mediated IgE class-switching, and T H 2 immunity. [37] [38] [39] The lack of ICOS memory T-cell count decreases with age in pediatric AD supports the role of ongoing T-cell activation in disease maintenance and highlights the importance of T H 2 expansion in patients with early disease. In pediatric patients with AD, ICOS-activated T-cell counts correlate with memory and activated B-cell counts, emphasizing the role of ICOS in IgE class-switching and underscoring the mutual contribution of activated T-cell and B-cell counts to an early disease phenotype.
CD23 is the low-affinity IgE receptor, and its levels are negatively correlated with those of allergen-induced IgE. 40, 41 The significantly lower levels of CD23 expression in early childhood shown here might translate into a higher propensity toward IgE sensitization and atopy development. 42 CD23 also functions in antigen presentation, B-cell proliferation, and T-cell/B-cell interaction, [43] [44] [45] explaining its higher frequencies in patients with AD. 31 Chronic immune activation and antigenic exposure in patients with AD might account for the huge increase in CD23 expression from infancy to adulthood. 46, 47 Early T-cell predominance accompanied by positive correlations observed between activated memory T cells and CD23 1 (''allergic phenotype'') B cells fit the basic immunologic concept that T H 2 cells direct IgE class-switching. CD19 1 CD38
11
CD24
11 transitional cells constitute the earliest population emigrating from the BM during B-cell maturation. 48, 49 In patients with systemic lupus erythematosus, in whom B cells are pathogenic, there is a peripheral shift toward immature populations contributing to autoimmunity and defective tolerance. 50, 51 Although in adults with AD we showed transitional cell expansion, 19 
CD27
2 DN B cells are the only memory subset that does not increase with age. 15 Likewise, we show that DN B cells comprise the only subset that is higher in pediatric compared with adult patients with AD. Although the physiologic role of this subset is obscure, it is expanded in patients with autoimmune and infectious diseases. 54, 55 Thus its expansion in patients with early AD might reflect the potential role of infections/superantigens in disease initiation.
B-cell CD40 neonatal expression is similar to that seen in adults, 56 but undetectable CD40 ligand expression on neonatal T cells limits T-cell/B-cell interactions and IgE class-switching. 57, 58 Nevertheless, excessive IL-4 in patients with early AD leads to increased neonatal CD40 ligand expression and promotes IgE isotype switching. 59 Conventionally, T cells are involved in B-cell activation and IgE class-switching, 60 but T cell-independent pathways and IgE-selective unresponsiveness were reported. 61, 62 Furthermore, T H 2 activation is common to all AD forms, regardless of IgE status, supporting the hypothesis that factors other than T H 2 elicit IgE responses. 1 An altered microbiome in patients with AD 63 might also facilitate early development of IgE-mediated food allergies. 64 These data advocate for involvement of B cells and IgE sensitization in patients with early AD and initiation of the atopic march.
In early life there are limited T cell-independent antibody responses to polysaccharide antigens. Although other pathways are immature, protein antigens (eg, milk and peanut) can induce antibody responses in a T cell-dependent mechanism. 65 The high occurrence of protein allergen IgE sensitization in our young AD group supports the importance of activated T cells in initiating the atopic march. CD19 
IgD
1 CD27 1 NSM B cells represent a heterogeneous population and play a role in T cell-independent antigen responses. 14, 66, 67 High levels at birth decrease during childhood with simultaneous increases of SM cells. 34 Our results support low numbers of this subset in early childhood.
33 Their significantly low occurrence in pediatric versus adult patients with AD might contribute to the low propensity toward polysaccharides, as opposed to the T cell-dependent protein antigen hypersensitivity shown here. Conversely, although the B-cell/T-cell ratio decrease with age was exclusively observed in control subjects, positive correlation with NSM B cells was documented selectively in patients with AD. Thus in addition to maintaining a ''high B-cell profile,'' the NSM subset is relatively conserved in children with AD, possibly indicating the plasticity of their immune system and increased potential to develop T cell-independent hypersensitivities. The importance of this B-cell subset in patients with early AD is further accentuated by multiple positive correlations observed with activated T cells. Studies showed that children with severe AD have higher allergen IgE sensitizations. 68 Although these do not necessarily predict development of clinical allergies, 69, 70 they might play a role in disease induction. 71 Likewise, our data show significantly increased IgE sensitization in pediatric patients with AD. This is further supported by multiple positive correlations with SCORAD scores. The fact that a great proportion of allergens clustered together with age in pediatric patients with AD fits the immunologic concept of later development of food allergies rather than being a primary event. Although sIgEs account for only 20% to 50% of total IgE 72, 73 and despite the polyclonal activation in patients with AD, 72 in our pediatric AD cohort virtually all sIgEs correlated with total IgE levels, which also correlated with age.
Because SEB is associated with local infections, higher occurrence of SEB than SEA sensitization was reported in patients with AD, 74 and indeed, only SEB levels correlate positively with SCORAD scores in our cohort. The high cooccurrence of SEA/SEB with various food sensitizations might implicate S aureus in AD initiation and, as suggested by Leung et al, 75 in triggering food allergies in children with AD. Clustering of multiple sIgEs with T H 1/T H 2 lymphocytes and B-cell subsets and the positive correlation observed between memory B-and T-cell counts support the notion that a complex immune network orchestrates early AD and initiation of the atopic march.
There were several limitations to this study. First, it presents only a single point in time, although it might be desirable to study skin before and after AD onset in high-risk infants. Thus the chicken or egg dilemma of the initial pathogenic incident in patients with AD remains, and longitudinal studies are required. Additionally, because obtaining blood at this young age is extremely challenging, we were not able to also perform complete blood counts and thus were not able to calculate absolute numbers.
In sum, given the early T-cell dominance, age-dependent B-cell changes, and associations between memory B-cell and T H 2 cell subsets, one can hypothesize that cutaneous disease begins as a T-cell disease with little B-cell involvement, whereas in blood there is a pathologic emergence of accelerated B-cell development and IgE class-switching. In patients with early AD, only T H 2 cells are detected in blood 13 ; because they contain Tcm cells, this might indicate an ongoing crosstalk with B cells in lymph nodes (see Fig E5 in this article' s Online Repository at www. jacionline.org) to create the atopic march. Two major questions remain: What is the ultimate primary prevention for AD, and can immune manipulation halt the secondary ensuing of the atopic march, once skin disease has developed? Future studies will have to determine whether early T-cell targeting administered in the narrow window of opportunity opened between AD development and initiation of other atopic diseases is beneficial in stopping the march. 
IHC
Frozen sections of normal (n 5 7/n 5 14 [children/adults]), AD lesional (n 5 14/n 5 32), and AD nonlesional (n 5 12/n 5 16) skin sections were blocked with 10% normal horse serum and stained with CD20 and CD3 mouse mAbs (Abcam, Cambridge, Mass). Biotin-labeled horse anti-mouse antibodies (Vector Laboratories, Burlingame, Calif) were used to detect mouse mAbs. The staining signal was amplified with avidin-biotin complex (Vector Laboratories, Burlingame, Calif) and developed with chromogen 3-amino-9-ethylcarbazole (Sigma-Aldrich, St Louis, Mo). The number of positive cells per millimeter of epidermis surface length was counted manually by using computer-assisted image analysis (National Institutes of Health ImagJe 6.1; http://rsb.info.nih.gov/NIH-image). 
FIG E4.
Unsupervised hierarchical clustering of B cells and activated memory T cells for pediatric control subjects by using Spearman correlation as a similarity metric. Contrary to AD, nonsignificant correlations and lack of clustering were observed between major B-cell and T-cell subsets. *P < .05, **P < .01, and ***P < .001. 
